Русский
Peculiarities of cardiovascular outcomes in male and female patients after novel coronavirus infection caused by SARS-CoV-2
DOI: https://dx.doi.org/10.18565/therapy.2022.9.34-42
Glibko K.V., Arakelov S.E., Titova I.Yu., Kasaeva D.A., Larina V.N.
1) N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow; 2) City Clinical Hospital No. 13 of the Department of Healthcare of Moscow; 3) Medical Institute of Peoples’ Friendship University of Russia, Moscow
The aim of the study is to evaluate cardiovascular outcomes in male and female patients after COVID-19 infection.
Material and methods. 658 patients aged 25–59 years and underwent a preventive medical examination were included in open comparative study. Depending on the presence or absence of COVID-19 history in anamnesis, they were divided into the main group (n=416, median age 40 (33; 47) years) and the comparison group (n=242, median age 41 (34; 47) years). The main group included 361 (86,8%) females and 55 (13,2%) males, the comparison group included 197 (81,4%) females and 45 (18,6%) males (p=0,083). Demographic indicators, risk factors, cardiovascular risk (CVR) were assessed. A year later, the abovementioned indicators, incidence of COVID-19 and new cases of arterial hypertension (AH), coronary artery disease, and diabetes mellitus were re-registered.
Results. After previous COVID-19, arterial hypertension was first diagnosed in 8% (p=0,001) of female and 14,6% (p=0,058) of male patients. A higher incidence in females with overweight (78,1%; p=0,001), hyperglycemia (52%; p=0,001) and moderate cardiovascular risk (61,7%; p=0,008) was fixed. The number of females with high (p=0,037) and very high CVR (p=0,037) increased, and the number of females with low CVR decreased (p=0.001). After previous COVID-19, all male smokers quit smoking (p<0.001), while the number of men with overweight (89%; p=0,001) and very high CVR (25,4%; p=0,002) increased. IHD was diagnosed in 2,8% (p=0,082) of females and 7,2% of males (p=0,126), diabetes mellitus in 3,9% (p=0,012) of females and 5,4% of males (p=0,434) within a median of 3 (2; 4) months after suffering from COVID-19.
Conclusion. Females aged 25 to 59 years old with moderate CV risk, overweight, smoking, 3 or more cardiovascular disease (CVD) risk factors, and males of similar age with 3 or more CVD risk factors and smoking who have had COVID-19 infection, should cause medical alertness regarding CVD development.
Literature
1. Dhakal B.P., Sweitzer N.K., Indik J.H. et al. SARS-cov-2 Infection and cardiovascular disease: COVID-19 heart. Heart Lung Circ. 2020; 29(7): 973–87. https://dx.doi.org/10.1016/j.hlc.2020.05.101.
2. Yang J., Zheng Y., Gou X. et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: A systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91–95. https://dx.doi.org/10.1016/ j.ijid.2020.03.017.
3. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239–42. https://dx.doi.org/10.1001/jama.2020.2648.
4. Мелехов А.В., Агаева А.И., Никитин И.Г. Симптоматика в отдаленном периоде после перенесенной коронавирусной инфекции: результаты длительного наблюдения. Архивъ внутренней медицины. 2022; 12(4): 302–309. [Melekhov A.V., Agaeva A.I., Nikitin I.G. Symptoms in the long period after the coronavirus infection: results of long-term follow-up. Arkhiv vnutrenney meditsiny = The Russian Archives of Internal Medicine. 2022; 12(4): 302–309 (In Russ.)].https://dx.doi.org/10.20514/2226-6704-2022-12-4-302-309. EDN: ANXLZG.
5. Williamson E.J., Walker A.J., Bhaskaran K. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821): 430–36. https://dx.doi.org/10.1038/s41586-020-2521-4.
6. Некаева Е.С., Большакова А.Е., Малышева Е.С. с соавт. Гендерные особенности новой коронавирусной инфекции (COVID-19) у лиц зрелого возраста. Современные технологии в медицине. 2021; 13(4): 16–26. [Nekaeva E.S., Bolshakova A.E., Malysheva E.S. et al. Gender characteristics of the novel coronavirus infection (COVID-19) in middle-aged adults. Sovremennye tekhnologii v meditsine = Modern Technologies in Medicine. 2021; 13(4): 16–26 (In Russ.)]. https://dx.doi.org/10.17691/stm2021.13.4.02. EDN: ITDEMX.
7. Petrilli C.M., Jones S.A., Yang J. et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study. BMJ. 2020; 369: m1966. https://dx.doi.org/10.1136/bmj.m1966.
8. Van Gerwen M., Alsen M., Little C. et al. Risk factors and outcomes of COVID-19 in New York City; A retrospective cohort study. J Med Virol. 2021; 93(2): 907–15. https://dx.doi.org/10.1002/jmv.26337.
9. Mcpadden J., Warner F., Young H.P. et al. Clinical characteristics and outcomes for 7,995 patients with SARS-cov-2 infection. PLOS One. 2021; 16(3): e0243291. https://dx.doi.org/10.1371/journal.pone.0243291.
10. Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г. с соавт. Международный регистр «Анализ динамики Коморбидных заболеваний у пациентов, перенесших инфицирование SARS-cov-2» (AКТИВ SARS-CoV-2): анализ предикторов неблагоприятных исходов острой стадии новой коронавирусной инфекции. Российский кардиологический журнал. 2021; 26(4): 116–131. [Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G. et al. International register «Dynamics analysis of comorbidities in SARS-CoV-2 survivors» (AKTIV SARS-CoV-2): analysis of predictors of short-term adverse outcomes in COVID-19. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26(4): 116–131 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2021-4470. EDN: IEXRNA.
11. Бойцов С.А., Погосова Н.В., Бубнова М.Г. с соавт. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018; 23(6): 7–122. [Boytsov S.A., Pogosova N.V., Bubnova M.G. et al. Cardiovascular prevention 2017. National guidelines. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018; 23(6): 7–122 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2018-6-7-122. EDN: XSLTTF.
12. Кобалава Ж.Д., Конради А.О., Недогода С.В. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(3): 149–218. [Kobalava Zh.D., Konradi A.O., Nedogoda S.V. et al. Arterial hypertension in adults. Clinical guidelines 2020. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 25(3): 149–218 (In Russ.)]. https://dx.doi.org/10.15829/1560–4071-2020-3-3786. EDN: TCRBRB.
13. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020; 23(S2): 4–102. [Dedov I.I., Shestakova M.V., Mayorov A.Yu. et al. Diabetes mellitus type 2 in adults. Sakharniy diabet = Diabetes Mellitus. 2020; 23(S2): 4–102 (In Russ.)]. https://dx.doi.org/10.14341/DM12507. EDN: YBRIMY.
14. Лукьянов М.М., Кутишенко Н.П., Марцевич С.Ю. с соавт. Отдаленные исходы у больных, перенесших COVID-19 (данные регистра ТАРГЕТ-ВИП). Российский кардиологический журнал. 2022; 27(3): 60–66. [Lukyanov M.M., Kutishenko N.P., Martsevich S.Yu. et al. Long-term outcomes in patients after COVID-19: data from the TARGET-VIP registry. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2022; 27(3): 60–66 (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2022-4912. EDN: YVXVXW.
15. Ротарь О.П., Ерина А.М., Бояринова М.А. с соавт. Контроль артериальной гипертензии в период пандемии коронавирусной инфекции: результаты российской акции скрининга МММ2021. Российский кардиологический журнал. 2022; 27(4): 7–13. [Rotar O.P., Erina A.M., Boyarinova M.A. et al. Hypertension control during the COVID-19 pandemic: results of the MMM2021 in Russia. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2022; 27(4): 7–13 (In Russ.)].https://dx.doi.org/10.15829/1560-4071-2022-5014. EDN: AVGCIE.
16. Sudre C.H., Murray B., Varsavsky T. et al. Attributes and predictors of long COVID. Nat Med. 2021; 27(4): 626–31.https://dx.doi.org/10.1038/s41591- 021-01292-y.
17. Арутюнов А.Г., Сеферович П., Бакулин И.Г. с соавт. Реабилитация после COVID-19. Резолюция Международного совета экспертов Евразийской ассоциации терапевтов и Российского кардиологического общества. Российский кардиологический журнал. 2021; 26(9): 135–151. [Arutyunov A.G., Seferovic P., Bakulin I.G. et al. Rehabilitation after COVID-19. Resolution of the International Expert Council of the Eurasian Association of Therapists and the Russian Society of Cardiology. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2021; 26(9): 135–151. (In Russ.)]. https://dx.doi.org/10.15829/1560-4071-2021-4694. EDN: QMZBRF.
18. Трисветова Е.Л. Синдром постуральной ортостатической тахикардии как проявление постковидного синдрома. Рациональная фармакотерапия в кардиологии. 2022; 18(2): 200–208. [Trisvetova E.L. Postural orthostatic tachycardia syndrome as a manifestation of post-COVID-19 syndrome. Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2022; 18(2): 200–208 (In Russ.)]. https://dx.doi.org/10.20996/1819-6446-2022-04-11. EDN: TXWNOC.
19. Дворников А.С., Силин А.А., Гайдина Т.А. с соавт. Кожные проявления при коронавирусной болезни 2019 года (COVID-19). Архивъ внутренней медицины. 2020; 10(6): 422–429. [Dvornikov A.S., Silin A.A., Gaydina T.A., Larina V.N., Skripkina P.A., Kiva E.V. The dermatological manifestations in the coronavirus infection COVID-19. Arkhiv vnutrenney meditsiny = The Russian Archives of Internal Medicine. 2020; 10(6): 422–429 (In Russ.)]. https://dx.doi.org/10.20514/2226-6704-2020-10-6-422-429. EDN: OQCWVF.
20. Вахненко Ю.В., Доровских И.Е., Домке А.П. Кардиоваскулярная составляющая постковидного синдрома. Тихоокеанский медицинский журнал. 2022; 1: 56–64. [Vakhnenko Y.V., Dorovskikh I.E., Domke A.P. Cardiovascular component of post-COVID-19-syndrome. Tikhookeanskiy meditsinskiy zhurnal = Pacific Medical Journal. 2022; 1: 56–64 (In Russ.)].https://dx.doi.org/10.34215/1609-1175-2022-1-56-64. EDN: CMYOVY.
21. Ларина В.Н., Головко М.Г., Ларин В.Г. Влияние коронавирусной инфекции (COVID-19) на сердечно-сосудистую систему. Вестник Российского государственного медицинского университета. 2020; 2: 5–13. [Larina V.N., Golovko M.G., Larin V.G. Possible effects of coronavirus infection (COVID-19) on the cardiovascular system. Vestnik Rossiyskogo gosudarstvennogo meditsinskogo universiteta = Herald of the Russian State Medical University. 2020; 2: 5–13 (In Russ.)]. https://dx.doi.org/10.24075/vrgmu.2020.020.
About the Autors
Kirill V. Glibko, assistant at the Department of polyclinic therapy of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, general practitioner of City Clinical Hospital No. 13 of the Department of Healthcare of Moscow. Address: 115280, Moscow, 1/1 Velozavodskaya Str. E-mail: glibkokv@zdrav.mos.ru. ORCID: https://orcid.org/0000-0001-7331-2791. SPIN-code: 1510-7979
Sergei E. Arakelov, Dr. med. habil., head of the Department of family medicine with a course of palliative care of the Faculty of continuing medical education, Medical Institute of Peoples’ Friendship University of Russia, chief physician of City Clinical Hospital No. 13 of the Department of Healthcare of Moscow. Address: 115280, Moscow, 1/1 Velozavodskaya Str. ORCID: https://orcid.org/0000-0003-3911-8543
Irina Yu. Titova, deputy chief physician of the medical unit of City Clinical Hospital No. 13 of the Department of Healthcare of Moscow. Address: 115280, Moscow, 1/1 Velozavodskaya Str. ORCID: https://orcid.org/0000-0001-7056-0634
Diana A. Kasaeva, head of the polyclinic of City Clinical Hospital No. 13 of the Department of Healthcare of Moscow. Address: 115280, Moscow, 1/1 Velozavodskaya Str. ORCID: https://orcid.org/0000-0003-1419-9666
Vera N. Larina, Dr. med. habil., professor, head of the Department of polyclinic therapy of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityanova Str. E-mail: larinav@mail.ru. ORCID: https://orcid.org/0000-0001-7825-5597
Similar Articles
